Citius Pharmaceuticals provides update on Mino-Lok Phase 3 trial

Citius Pharmaceuticals has advanced its clinical trial for Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Of the 92 events required to complete the trial, the company estimates that 85 events have been achieved to date. The trial has enrolled 190 patients, of which 16 patients are in active treatment or pending study completion data review, which may result in additional events. The multi-center Mino-Lok Phase 3 trial continues to recruit patients at 35 clinical trial sites in the U.S. and India. The primary endpoint for this study is the time to a catheter failure event between randomization and TOC in the Intent-to-Treat Population. Additional secondary outcome measures include overall success, microbiological eradication, and clinical cure, among others.